The use of glyburide compared with other sulfonylureas and the risk of cancer in patients with type 2 diabetes

Diabetes Care

Volumn 38, Issue 11, 2015, Pages 2083-2089

  Tuccori, Marco ^a   Wu, Jennifer W ^a,b   Yin, Hui ^a   Majdan, Agnieszka ^c   Azoulay, Laurent ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RISK ASSESSMENT; TREATMENT DURATION; UNITED KINGDOM; AGED; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; NEOPLASMS; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84962374171     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1358     Document Type: Article

References (40)

1. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.
2. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007;23:479-484.
3. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258.
4. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777.
5. Kawaguchi T, Taniguchi E, Morita Y, et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010;30:479-486.
6. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: A casecontrol study. Acta Diabetol 2009;46:279-284.
7. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes- related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013;98:668-677.
8. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: A study with the General Practice Research Database and secondary care data. Diabetologia 2012;55:654-665.
9. Monami M, Colombi C, Balzi D, et al.Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011; 34:129-131.
10. Sun GE, Wells BJ, Yip K, et al. Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:276-283.
11. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow- up study. Diabetes Care 2012;35:119-124.
12. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: A retrospective analysis. Diabetes Care 2010;33:1224-1229.
13. Bo S, Castiglione A, Ghigo E, et al. Mortality outcomes of different sulphonylurea drugs: The results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol 2013;169:117-126.
14. Sawada F, Inoguchi T, Tsubouchi H, et al. Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6. Metabolism 2008;57:1038-1045.
15. Pasello G, Urso L, Conte P, Favaretto A. Effects of sulfonylureas on tumor growth: A review of the literature. Oncologist 2013;18:1118-1125.
16. Yang X, So WY, Ma RC, et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010;90:343-351.
17. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: A population-based case-control study. Am J Epidemiol 2008;168:925-931.
18. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350: 1097-1099.
19. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-689.
20. Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
21. Bell DS, Patil HR, O'Keefe JH. Divergent effects of various diabetes drugs on cardiovascular prognosis. Rev Cardiovasc Med 2013;14: e107-e122.
22. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625.
23. Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: A cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 2014;37:2522-2532.
24. Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012;35:2665-2673.
25. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009; 124:1398-1403.
26. Núnez M, Medina V, Cricco G, et al. Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDAMB- 231. BMC Pharmacol Toxicol 2013;14:6.
27. Yasukagawa T, Niwa Y, Simizu S, Umezawa K. Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells. FEBS Lett 2012;586:1504-1509.
28. Sliwinska A, Sliwinski T, Kasznicki J, Drzewoski J. Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. J Physiol Pharmacol 2010;61:347-353.
29. Qi C, Zhou Q, Li B, et al. Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. Oncotarget 2014;5:9966-9979.
30. de Sant'Anna JR, Franco CC, Mathias PC, de Castro-Prado MA. Assessment of in vivo and in vitro genotoxicity of glibenclamide in eukaryotic cells. PLoS One 2015;10:e0120675.
31. Sliwinska A, Blasiak J, Drzewoski J. Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells. Chem Biol Interact 2006;162:259-267.
32. O'Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000;14:201-206.
33. Pan HZ, Chang D, Feng LG, Xu FJ, Kuang HY, Lu MJ. Oxidative damage to DNA and its relationship with diabetic complications. Biomed Environ Sci 2007;20:160-163.
34. Maguire A, Mitchell BD, Ruzafa JC. Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: A retrospective cohort study. BMC Endocr Disord 2014;14:73.
35. Wheeler S, Moore K, Forsberg CW, et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia 2013;56: 1934-1943.
36. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-920.
37. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-499.
38. McGovern MP, Boroujerdi MA, Taylor MW, et al. The effect of the UK incentive-based contract on the management of patients with coronary heart disease in primary care. Fam Pract 2008;25:33-39.
39. Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf 2013; 22:168-175.
40. Cancer Research UK. Cancer incidence by age [article online], 2014. Available from http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age#heading-Zero. Accessed 19 June 2015.